Shift.ms is better if you're logged in

Reposted from the MS Research blog at Barts. 'There are loads of anti CD19 CAR-T cell therapies arriving. It is going to be some time before this mature but it will work the question will be the balance of side effects and efficacy and value over current anti CD20 depleters P108. A Phase 1 Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Progressive Forms of Multiple Sclerosis P096. An Investigator Initiated Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis P103. A Phase 1, Multicenter, Single-Arm, Dose-Escalation Study of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process, Evaluating Safety and Tolerability in Patients With Relapsing or Progressive Forms of Multiple Sclerosis (Breakfree-2)' Courtesy of Mouse Doctor (Prof Baker)